Skip to main content
logo
Anbio Biotechnology (NNNN)
NASDAQ: NNNN · Real-Time Price · USD
7.75
-0.60 (-7.19%)
Aug 19, 2026, 4:00 PM EDT - Market closed

Anbio Biotechnology Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.

Operating Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
6.42.372.2510.012.54
Depreciation & Amortization
--0.010.01-
Loss (Gain) From Sale of Investments
0.07-0.34-0.16-0.04-
Change in Accounts Receivable
-2.590.82-1.880.72-0.72
Change in Inventory
--0.35-0.35-
Change in Accounts Payable
-1.630.8-0.58-0.481.89
Change in Other Net Operating Assets
-8.99-1.570.91-5.410.47
Operating Cash Flow
-6.742.080.94.454.18
Operating Cash Flow Growth
-131.57%-79.81%6.40%-

Investing Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Investment in Securities
-4.20.341.73-1.53-
Investing Cash Flow
-4.20.341.73-1.53-

Financing Activities

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Issuance of Common Stock
7.23----
Other Financing Activities
-0.28-0.34-0.04--
Financing Cash Flow
6.95-0.34-0.04--

Net Cash Flow

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Cash Flow
-3.992.072.592.924.18

Free Cash Flow

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Levered Free Cash Flow
-9.611.270.030.87-
Unlevered Free Cash Flow
-9.611.270.030.87-

Additional Metrics

Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Change in Working Capital
-13.210.04-1.2-5.531.65
SEC Filings: 10-K · 10-Q